Executive Summary
NASA's $85.4M obligated delivery order to Caltech (nonprofit) for JPL's PO.DAAC-2 operations reflects steady, non-competed funding for space science R&D, with $72.4M (85%) already outlayed from an $89.6M ceiling. Neutral signal limits direct equity upside, but $4.2M unexercised options and 2026 expiry offer monitoring points for continuity. Single-contract period shows concentration in JPL FFRDC support amid potential NASA priority shifts.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Tracking the trend? Catch up on the prior NASA & Space Contracts Intelligence digest from March 18, 2026.
Risk Flags (2)
- Execution [MEDIUM RISK]▼
Heavy reliance on NASA task orders for remaining funding realization
- Market [HIGH RISK]▼
Exposure to NASA funding priority changes over long 8-year period ending 2026-09-30
Opportunities (2)
- ◆
$4.2M unexercised options within $89.6M ceiling
- ◆
Potential extension of JPL FFRDC operations for PO.DAAC-2 beyond 2026
Sector Themes (1)
- ◆
Non-competed Cost Plus Fixed Fee order sustains PO.DAAC-2 for physical oceanography R&D under NAICS 541715.
Watch List (2)
- 👁
{"entity"=>"California Institute of Technology / JPL", "reason"=>"$85.4M obligation nears $89.6M ceiling with 2026 expiry", "trigger"=>"Option exercises, task orders, or follow-on solicitations"}
- 👁
{"entity"=>"NASA Management Office -- JPL Task Orders", "reason"=>"Drives realization of remaining value in non-competed FFRDC support", "trigger"=>"Issuances impacting PO.DAAC-2 funding"}
Get daily alerts with 2 risk alerts, 2 opportunities and full AI analysis of all 1 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: NASA & Space Contracts Intelligence
🇺🇸 More from United States
View all →May 27, 2026
US Pre-Market SEC Filings Roundup — May 27, 2026
US Pre-Market SEC Filings Roundup
May 27, 2026
S&P 500 Technology Sector SEC Filings — May 27, 2026
S&P 500 Technology Sector SEC Filings
May 27, 2026
Orphan Drug Approvals — May 27, 2026
Orphan Drug Approvals
May 27, 2026
Big Pharma Approvals — May 27, 2026
Big Pharma Approvals